Insider Buying: Global Medical REIT (NYSE:XRN) Director Acquires $991,944.00 in Stock

Global Medical REIT Inc. (NYSE:XRN) Director Charles Fitzgerald acquired 27,600 shares of the firm’s stock in a transaction on Monday, August 10th. The stock was purchased at an average cost of $35.94 per share, for a total transaction of $991,944.00. Following the completion of the acquisition, the director owned 124,893 shares in the company, valued at approximately $4,488,654.42. This represents a 28.37% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Charles Fitzgerald also recently made the following trade(s):

• On Tuesday, August 11th, Charles Fitzgerald bought 14,000 shares of Global Medical REIT stock. The stock was acquired at an average cost of $35.78 per share, with a total value of $500,920.00.

Global Medical REIT Trading Up 1.9%

Shares of Global Medical REIT stock opened at $37.28 on Friday. The company has a debt-to-equity ratio of 1.37, a quick ratio of 0.68 and a current ratio of 0.59. The firm has a 50-day moving average of $36.62 and a 200-day moving average of $35.81. Global Medical REIT Inc. has a 52-week low of $29.05 and a 52-week high of $39.93. The stock has a market cap of $493.59 million, a PE ratio of 10.02 and a beta of 1.09.

Global Medical REIT (NYSE:XRN) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $4.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.83 by $3.95. Global Medical REIT had a net margin of 36.82% and a return on equity of 13.31%. The firm had revenue of $39.75 million during the quarter. As a group, sell-side analysts forecast that Global Medical REIT Inc. will post 2.89 EPS for the current year.

Key Global Medical REIT News

Here are the key news stories impacting Global Medical REIT this week:

• Positive Sentiment: CEO Mark Okey Decker, Jr. bought 8,000 shares at $35.88 and an additional 6,875 shares at $35.92, while COO Aaron Robert Roseth purchased 13,500 shares at $36.73. Director Charles Fitzgerald also acquired 14,000 shares at $35.78. The reported purchases represent more than $1.5 million of direct insider buying, a potentially bullish signal. Global Medical REIT CEO Purchases Shares
• Positive Sentiment: Global Medical REIT’s latest quarterly results significantly exceeded expectations: earnings per share were $4.78 versus the $0.83 consensus estimate, with revenue of $39.75 million. The company also reported a 36.82% net margin and 13.74% return on equity, providing fundamental support for investor interest.
• Neutral Sentiment: Analyst opinion remains mixed, with two Buy ratings, five Holds and one Sell. The average price target is $40.25, above the recent trading range, but Compass Point maintains a $38 target while Citizens JMP has a $42 target. The overall consensus rating is Hold.
• Neutral Sentiment: Institutional investors own approximately 57.52% of XRN. Recent filings show several funds increasing positions, although the disclosed transactions are not necessarily a near-term catalyst.
• Neutral Sentiment: Coverage also discusses Global Medical REIT’s rebranding and transition to Chiron Real Estate, which may create uncertainty about the company’s identity and strategic direction. Chiron Real Estate rebrand article
• Negative Sentiment: The REIT remains relatively leveraged, with a debt-to-equity ratio of 1.68 and current and quick ratios of 0.68. High debt and limited liquidity could weigh on valuation if interest rates stay elevated or healthcare property conditions weaken.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on XRN shares. Wall Street Zen downgraded Global Medical REIT from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. BMO Capital Markets raised their price target on Global Medical REIT from $39.00 to $40.00 and gave the stock a “market perform” rating in a research report on Monday, July 13th. Weiss Ratings downgraded Global Medical REIT from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, July 30th. Raymond James Financial started coverage on shares of Global Medical REIT in a research report on Wednesday, June 17th. They set a “market perform” rating for the company. Finally, Zacks Research upgraded shares of Global Medical REIT to a “hold” rating in a research note on Wednesday, July 22nd. Two analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $40.25.

Institutional Trading of Global Medical REIT

Several institutional investors and hedge funds have recently modified their holdings of XRN. Caitong International Asset Management Co. Ltd lifted its stake in shares of Global Medical REIT by 1,001.4% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 793 shares of the company’s stock valued at $27,000 after acquiring an additional 721 shares during the last quarter. Fifth Third Bancorp grew its position in Global Medical REIT by 35.3% during the 4th quarter. Fifth Third Bancorp now owns 1,417 shares of the company’s stock worth $48,000 after acquiring an additional 370 shares during the last quarter. Tower Research Capital LLC TRC grew its position in Global Medical REIT by 70.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,379 shares of the company’s stock worth $51,000 after acquiring an additional 3,046 shares during the last quarter. B. Riley Wealth Advisors Inc. acquired a new position in Global Medical REIT in the 2nd quarter worth about $78,000. Finally, Virtus Advisers LLC increased its holdings in Global Medical REIT by 46.5% in the 4th quarter. Virtus Advisers LLC now owns 2,418 shares of the company’s stock worth $82,000 after purchasing an additional 768 shares in the last quarter. 57.52% of the stock is currently owned by institutional investors.

Global Medical REIT Company Profile

Global Medical REIT (NYSE: GMRE) is a real estate investment trust focused on owning and managing healthcare-related properties across the United States. The company acquires, develops and leases a diversified portfolio of medical office buildings, outpatient facilities, long-term care centers and other specialized healthcare real estate. By concentrating on essential healthcare assets, Global Medical REIT seeks to generate stable, long-term rental income under triple-net and modified gross lease structures.

Since its incorporation in 2016 and initial public offering in 2017, the company has pursued an acquisitive growth strategy targeting markets with strong demographic trends and limited supply of modern medical facilities.